Journal Information

On this page: Aims & Scope | Our publishing models | Journal Metrics | Abstracted/indexed in | ISSN and E-ISSN | Newsfeeds

Aims and scope

Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management.

Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis.

Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.

The following is a non-exhaustive list of the general topics covered by Prostate Cancer and Prostatic Diseases:

  • Alternative therapies
  • Angiogenesis
  • Anti-sense oligonucleotides against growth factors
  • Brachytherapy
  • Conformal radiotherapy
  • Conformal radiotherapy
  • Cyclotron fast neutron treatment
  • Enhancing the results of radical prostatectomy
  • Epidemiology of prostate cancer and prostatic diseases
  • Familial prostate cancer
  • Free to total PSA
  • Gene therapy for prostate cancer
  • Genetic basis for prostate cancer Hormone-related disease
  • How significant is PSA-detected disease?
  • Intermittent antiandrogen therapy
  • Mechanisms of tumour invasion in prostate cancer
  • Medical and surgical therapies for male LUTS
  • Medical therapy for male LUTS: the road ahead
  • Natural history of prostate cancer and prostatic diseases
  • Nutrition in prostate cancer and prostatic diseases
  • Photodynamic therapy
  • Prognostic markers
  • Prostate cancer and potency and impotence
  • Prostatic intra-epithelial neoplasia - an important precursor of cancer
  • Prostatitis: quo vadis?
  • Quality of life issues
  • Racial issues in prostate cancer
  • Recurrence after radical prostatectomy
  • Reproducibility (test-retest reliability) of investigations for prostatic diseases
  • Reverse transcriptase polymerase chain reaction to detect circulating mRNA for PSA
  • Role of differentiation therapy
  • Screening for prostate cancer
  • Staging of prostate cancer: beyond conventional imaging
  • The magic bullet - use of PSA promotor gene to target gene therapy
  • Utility of ultrasensitive PSA assays

Submit your next manuscript to Prostate Cancer and Prostatic Diseases and benefit from:

  • Rapid turnaround times- less than 25 days for an initial decision
  • One of the highest ranked Urology journals
  • Wide exposure and article visibility via
  • Funder-compliant open access options available
  • Articles promoted via Twitter and online Collections
  • Free Advicefrom Springer Nature’s Research Data Services
  • Share your article- authors can use SharedIt to share view-only full text content from this journal

Our publishing models   

Prostate Cancer and Prostatic Diseases is a Transformative Journal (TJ). When research is accepted for publication, authors can choose to publish using either the traditional publishing route OR via immediate gold Open Access. 

Prostate Cancer and Prostatic Diseases is actively committed to becoming a fully Open Access journal. We will increase the number of articles we publish OA, with the eventual goal of becoming a fully Open Access journal. A journal that commits to this process is known as a Transformative Journal. 

Find out more about Transformative Journals

Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates. If your research is supported by a funder that requires immediate open access (e.g. according to Plan S principles) then you should select the gold OA route, and we will direct you to the compliant route where possible. For authors selecting the subscription publication route our standard licensing terms will need to be accepted including our self-archiving policies. Those standard licensing terms will supersede any other terms that the author or any third party may assert apply to any version of the manuscript.

Journal Metrics

The 2020 peer review performance metrics for Prostate Cancer and Prostatic Diseases are shown below:

Average time to decision without external review - 7 days
Average time to decision following external review - 31 days
Article page views - 294,533

The 2020 journal metrics* for Prostate Cancer and Prostatic Diseases are as follows:

2-year Impact Factor*: 5.554
5-year Impact Factor*: 4.837
Immediacy index*: 1.454
Eigenfactor® score*: 0.00515
Article influence score*: 1.534
Journal Citation Score*: 1.25

SNIP: 1.215
SJR: 0.377

*2020 Journal Citation Reports® Science Edition (Clarivate Analytics, 2020)

For more information on these journal metrics, please visit this link

Abstracted/indexed in

Current Contents/Clinical Medicine
EMBASE/Excerpta Medica
MEDLINE/Index Medicus
Research Alert
Science Citation Index
Science Citation Index Expanded
UK Health Centre Index


The international standard serial number (ISSN) for Prostate Cancer and Prostatic Diseases is 1365-7852, and the electronic international standard serial number (eISSN) is 1476-5608.


Prostate Cancer and Prostatic Diseases now provides its latest table of contents as an RSS web feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.

ReceiveProstate Cancer and Prostatic Diseases's current issue table of contents.

Find out more about RSS feeds, how to download an RSS reader and see all the newsfeeds offered by Nature Publishing Group.